Literature DB >> 10205268

Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.

T R Rebbeck1, P W Kantoff, K Krithivas, S Neuhausen, M A Blackwood, A K Godwin, M B Daly, S A Narod, J E Garber, H T Lynch, B L Weber, M Brown.   

Abstract

Compared with the general population, women who have inherited a germline mutation in the BRCA1 gene have a greatly increased risk of developing breast cancer. However, there is also substantial interindividual variability in the occurrence of breast cancer among BRCA1 mutation carriers. We hypothesize that other genes, particularly those involved in endocrine signaling, may modify the BRCA1-associated age-specific breast cancer risk. We studied the effect of the CAG repeat-length polymorphism found in exon 1 of the androgen-receptor (AR) gene (AR-CAG). AR alleles containing longer CAG repeat lengths are associated with a decreased ability to activate androgen-responsive genes. Using a sample of women who inherited germline BRCA1 mutations, we compared AR-CAG repeat length in 165 women with and 139 women without breast cancer. We found that women were at significantly increased risk of breast cancer if they carried at least one AR allele with >/=28 CAG repeats. Women who carried an AR-CAG allele of >/=28, >/=29, or >/=30 repeats were given a diagnosis 0.8, 1.8, or 6.3 years earlier than women who did not carry at least one such allele. All 11 women in our sample who carried at least one AR-CAG allele with >/=29 repeats had breast cancer. Our results support the hypothesis that age at breast cancer diagnosis is earlier among BRCA1 mutation carriers who carry very long AR-CAG repeats. These results suggest that pathways involving androgen signaling may affect the risk of BRCA1-associated breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205268      PMCID: PMC1377873          DOI: 10.1086/302366

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  21 in total

1.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.

Authors:  A R La Spada; E M Wilson; D B Lubahn; A E Harding; K H Fischbeck
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

2.  Hormone-dependent regulation of BRCA1 in human breast cancer cells.

Authors:  J M Gudas; H Nguyen; T Li; K H Cowan
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

Review 3.  Role of the androgen receptor in human breast cancer.

Authors:  S N Birrell; R E Hall; W D Tilley
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

4.  Risk modifiers in carriers of BRCA1 mutations.

Authors:  S A Narod; D Goldgar; L Cannon-Albright; B Weber; R Moslehi; E Ives; G Lenoir; H Lynch
Journal:  Int J Cancer       Date:  1995-12-20       Impact factor: 7.396

5.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

6.  Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer.

Authors:  J M Hakimi; M P Schoenberg; R H Rondinelli; S Piantadosi; E R Barrack
Journal:  Clin Cancer Res       Date:  1997-09       Impact factor: 12.531

7.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.

Authors:  N L Chamberlain; E D Driver; R L Miesfeld
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

8.  Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies.

Authors:  P Kazemi-Esfarjani; M A Trifiro; L Pinsky
Journal:  Hum Mol Genet       Date:  1995-04       Impact factor: 6.150

9.  Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.

Authors:  S A Gayther; W Warren; S Mazoyer; P A Russell; P A Harrington; M Chiano; S Seal; R Hamoudi; E J van Rensburg; A M Dunning; R Love; G Evans; D Easton; D Clayton; M R Stratton; B A Ponder
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

10.  Androgens induce divergent proliferative responses in human breast cancer cell lines.

Authors:  S N Birrell; J M Bentel; T E Hickey; C Ricciardelli; M A Weger; D J Horsfall; W D Tilley
Journal:  J Steroid Biochem Mol Biol       Date:  1995-05       Impact factor: 4.292

View more
  49 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Decision tree-based modeling of androgen pathway genes and prostate cancer risk.

Authors:  Jill S Barnholtz-Sloan; Xiaowei Guan; Charnita Zeigler-Johnson; Neal J Meropol; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

3.  Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer.

Authors:  Andrei Anghel; Marius Raica; Catalin Marian; Sorin Ursoniu; Oana Mitrasca
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

Review 4.  Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  David J Hughes
Journal:  Fam Cancer       Date:  2008-02-19       Impact factor: 2.375

5.  Heredity, diet and lifestyle as determining risk factors for the esophageal cancer on Nanao Island in Southern China.

Authors:  Min Liu; Min Su; Dong-Ping Tian; Guo-Hong Zhang; He-Lin Yang; Yu-Xia Gao
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

6.  High frequency of skewed X inactivation in young breast cancer patients.

Authors:  M Kristiansen; A Langerød; G P Knudsen; B L Weber; A L Børresen-Dale; K H Orstavik
Journal:  J Med Genet       Date:  2002-01       Impact factor: 6.318

7.  Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.

Authors:  Sharon Simchoni; Eitan Friedman; Bella Kaufman; Ruth Gershoni-Baruch; Avi Orr-Urtreger; Inbal Kedar-Barnes; Ronit Shiri-Sverdlov; Efrat Dagan; Sigal Tsabari; Mordechai Shohat; Raphael Catane; Mary-Claire King; Amnon Lahad; Ephrat Levy-Lahad
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

8.  A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.

Authors:  A C Antoniou; P D P Pharoah; G McMullan; N E Day; M R Stratton; J Peto; B J Ponder; D F Easton
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

Review 9.  [Limb girdle muscular dystrophies].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

10.  Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.

Authors:  Susan L Neuhausen; Sean Brummel; Yuan Chun Ding; Christian F Singer; Georg Pfeiler; Henry T Lynch; Katherine L Nathanson; Timothy R Rebbeck; Judy E Garber; Fergus Couch; Jeffrey Weitzel; Steven A Narod; Patricia A Ganz; Mary B Daly; Andrew K Godwin; Claudine Isaacs; Olufunmilayo I Olopade; Gail Tomlinson; Wendy S Rubinstein; Nadine Tung; Joanne L Blum; Daniel L Gillen
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.